Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Sternberg

Showing results (471-480 of 564) with videos related to

Pageof 57
Sort By:
Cancer Medicine|November 11, 2024
Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysisMotohide Uemura, Hiroaki Kikukawa, Yasuhiro Hashimoto, et al.
European Urology|August 2, 2016
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL StudyTomasz M Beer, Andrew J Armstrong, Dana Rathkopf, et al.
Cells|January 11, 2022
Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell CarcinomaStephane Oudard, Nadine Benhamouda, Bernard Escudier, et al.
The Lancet. Oncology|February 22, 2014
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trialRobert J Motzer, Camillo Porta, Nicholas J Vogelzang, et al.
The New England Journal of Medicine|August 17, 2012
Increased survival with enzalutamide in prostate cancer after chemotherapyHoward I Scher, Karim Fizazi, Fred Saad, et al.
Urologic Oncology|July 15, 2020
Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survivalCamilla M Grunewald, Alina Henn, Matthew D Galsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2018
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial CancerDavid J Vaughn, Joaquim Bellmunt, Yves Fradet, et al.
The Oncologist|April 3, 2019
The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract CancerAristotelis Bamias, Kimon Tzannis, Christina Bamia, et al.
European Journal of Cancer (Oxford, England : 1990)|May 14, 2022
Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302Brooke E Wilson, Andrew J Armstrong, Johann de Bono, et al.
European Urology|September 15, 2023
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before MaintenanceSrikala S Sridhar, Thomas Powles, Miguel Á Climent Durán, et al.
Pageof 57

Showing results (471-480 of 564) with videos related to

Sort By:
Pageof 57
Cancer Medicine|November 11, 2024
Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysisMotohide Uemura, Hiroaki Kikukawa, Yasuhiro Hashimoto, et al.
European Urology|August 2, 2016
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL StudyTomasz M Beer, Andrew J Armstrong, Dana Rathkopf, et al.
Cells|January 11, 2022
Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell CarcinomaStephane Oudard, Nadine Benhamouda, Bernard Escudier, et al.
The Lancet. Oncology|February 22, 2014
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trialRobert J Motzer, Camillo Porta, Nicholas J Vogelzang, et al.
The New England Journal of Medicine|August 17, 2012
Increased survival with enzalutamide in prostate cancer after chemotherapyHoward I Scher, Karim Fizazi, Fred Saad, et al.
Urologic Oncology|July 15, 2020
Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survivalCamilla M Grunewald, Alina Henn, Matthew D Galsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2018
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial CancerDavid J Vaughn, Joaquim Bellmunt, Yves Fradet, et al.
The Oncologist|April 3, 2019
The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract CancerAristotelis Bamias, Kimon Tzannis, Christina Bamia, et al.
European Journal of Cancer (Oxford, England : 1990)|May 14, 2022
Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302Brooke E Wilson, Andrew J Armstrong, Johann de Bono, et al.
European Urology|September 15, 2023
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before MaintenanceSrikala S Sridhar, Thomas Powles, Miguel Á Climent Durán, et al.
Pageof 57